Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.55 |
| ▸ | CCR9 | P51686 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098431 | 0.86 | CCR2 (0.53) | CCR2CCR9 | |
| SCHEMBL4092463 | 0.83 | CCR2 (0.55) | CCR2CCR9 | |
| SCHEMBL4098695 | 0.80 | CCR2 (0.51) | CCR2CCR9 | |
| SCHEMBL4086022 | 0.78 | CCR2 (0.50) | CCR2CCR9PDE1BKDM4EPTGDR2 | |
| SCHEMBL4096957 | 0.75 | PTGES (0.52) | CCR2PDE1BKDM4ELMNAGAA | |
| SCHEMBL4086498 | 0.72 | TP53 (0.46) | CCR2CCR9 | |
| SCHEMBL4094156 | 0.71 | PTGES (0.43) | CCR2KDM4ELMNAHPGD | |
| SCHEMBL3957310 | 0.71 | CCR2 (1.00) | CCR2CCR9 | |
| SCHEMBL4091859 | 0.71 | KMT2A (0.47) | CCR2KDM4ELMNAHPGD | |
| SCHEMBL4097166 | 0.70 | CCR9 (0.45) | CCR2CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | CCR2 1118/4885CCR9 2391/4885PDE1B 3812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.